Obesity is classified as a chronic disease
Semaglutide is a single GLP-1 agonist with prior art going back to native GLP-1, exenatide, and liraglutide
What Real Patients Say: 2026 Feedback Trends In 2026, the conversation around IVIM Health has shifted from "Does it work?" to "How does it compare to brand-name drugs?" The Consensus on Results: The vast majority of patients report that the compounded medications from IVIM's partner pharmacies are indistinguishable from the brand-name versions in terms of appetite suppression and weight loss
Obviously, we need to assess for AEs, and the study is designed to see patients often and assess for AEs, but, as of yet, there are no concerning or worrisome AEs based on our research
Add a reputation grade of F, driven partly by passive-aggressive responses to public complaints, and the safety picture lands at a C